---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-24-000229"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:45:54.859010+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Biosciences launches CRENESSITY for classic CAH at WAC ~$38,333/month

## Summary
- CRENESSITY commercially available in U.S. for classic CAH (ages 4+); dispensed exclusively via PANTHERx Rare specialty pharmacy.
- Wholesale acquisition cost ~$38,333/30-day supply for adults; ~$19,167 for pediatric patients <20 kg.
- Company expects 90% of patients will have monthly copay of $12 or less through Neurocrine Access Support.
- CAH-trained pharmacists available 24/7 via PANTHERx Rare; free support program for patients and providers.

## SEC filing metadata
- accession: 0000914475-24-000229
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447524000229/0000914475-24-000229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447524000229/nbix-20241220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-24-000229
- JSON: https://secwatch.observer/filing/0000914475-24-000229.json
- Plain text: https://secwatch.observer/filing/0000914475-24-000229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.